
Cue Biopharma CUE
$ 0.29
21.83%
Quarterly report 2025-Q3
added 11-12-2025
Cue Biopharma DSO Ratio 2011-2025 | CUE
Annual DSO Ratio Cue Biopharma
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 51.9 | 58.3 | 469 | 55.7 | 164 | 79.7 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 469 | 51.9 | 146 |
Quarterly DSO Ratio Cue Biopharma
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19.5 | 22.8 | - | 68.4 | 60.9 | - | 60.8 | 43.9 | 61.7 | - | 534 | 1.62 K | 186 | - | 51 | 55.2 | 83.2 | - | 184 | 120 | 110 | - | 70 | 65.3 | 93.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.62 K | 19.5 | 185 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | ||
|
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
20.6 | $ 1.15 | -1.71 % | $ 6.27 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
31.5 | $ 4.78 | -0.31 % | $ 793 M | ||
|
Aclaris Therapeutics
ACRS
|
6.01 | $ 3.03 | -0.49 % | $ 234 M | ||
|
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | ||
|
Ascendis Pharma A/S
ASND
|
132 | $ 209.39 | -1.61 % | $ 5 B | ||
|
Aptevo Therapeutics
APVO
|
79 | $ 0.6 | -35.8 % | $ 166 K | ||
|
Alterity Therapeutics Limited
ATHE
|
16.2 K | $ 3.12 | 0.81 % | $ 7.51 B | ||
|
BioDelivery Sciences International
BDSI
|
115 | - | -4.8 % | $ 255 M | ||
|
Athersys
ATHX
|
22.6 | - | 3.77 % | $ 22.4 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
6.09 | - | -9.72 % | $ 5.89 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 0.22 | 24.46 % | $ 479 M | ||
|
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M | ||
|
Berkeley Lights
BLI
|
103 | - | -7.31 % | $ 87 M | ||
|
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
62.6 | $ 27.09 | 1.04 % | $ 1.31 B | ||
|
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B | ||
|
Calithera Biosciences
CALA
|
28.8 | - | -10.95 % | $ 876 K | ||
|
Anika Therapeutics
ANIK
|
77.3 | $ 9.6 | 1.27 % | $ 141 M | ||
|
bluebird bio
BLUE
|
2.47 | - | - | $ 546 M | ||
|
Zai Lab Limited
ZLAB
|
66 | $ 18.4 | -0.97 % | $ 18.2 B | ||
|
Catalyst Biosciences
CBIO
|
3.24 | $ 12.33 | -0.29 % | $ 812 M | ||
|
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | ||
|
Axon Enterprise
AXON
|
134 | $ 584.81 | -1.07 % | $ 44.3 B | ||
|
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
150 | $ 2.44 | -3.56 % | $ 15.3 M | ||
|
ChromaDex Corporation
CDXC
|
13.2 | - | -0.88 % | $ 598 M | ||
|
Certara
CERT
|
88.6 | $ 8.9 | -0.17 % | $ 1.43 B | ||
|
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K |